Ligand pharmaceuticals inc
LGND 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
LGND 近期報酬表現
1.59%
Ligand pharmaceuticals inc
0.98%
同產業平均
0.02%
S&P500
與 LGND 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TXG | 10x genomics inc | 2 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
VCYT | Veracyte inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
PACB | Pacific biosciences of california inc | 3 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 |
- TXG 10x genomics inc價值 2 分趨勢 1 分波段 1 分籌碼 3 分股利 1 分查看更多
LGND 公司資訊
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.